News Regeneron forges CAR-T R&D partnership with bluebird bio Deal combines Regeneron's receptor tech with CAR-T biotech's expertise
News Spectacular results for bluebird's gene therapy in thalassem... Patients with the rare blood disorders transfusion-dependent β-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird bio's gene therapy, raising hopes the treatmen
News Scotland's TC BioPharm joins bluebird to develop next-gen CA... US cancer biotech bluebird bio has joined with TC BioPharm in a collaboration focused on gamma delta CAR-T cells.
News More good news for Bluebird Bio with CALD gene therapy Bluebird Bio has presented encouraging data from its gene therapy treatment for t
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
